Psychedelic Renaissance: Evidence and Culture - Adrian Preda (Psychiatric News, 2024)

A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer - University of Utah (ClinicalTrials.gov, 2024)

Ethical considerations for psychedelic-assisted therapy in military clinical settings. - Hoener S; Wolfgang A; Nissan D; Howe E (Journal of medical ethics, 2024)

Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond. - Vandevelde M; Simoens A; Vandekerckhove B; Stevens C (RSC medicinal chemistry, 2024)

Five New Species of from Xizang Autonomous Region of China and Surrounding Areas. - Yang WQ; Li JX; He MQ; Wang SH; Zhu XY; Phurbu D; Yun JM; Zhao RL (Journal of fungi (Basel, Switzerland), 2024)

Scanning the new frontier of mental health: psychedelic brain imaging - Natalie Ertl; Matthew B. Wall (The Biochemist, 2024)

Psychedelic drugs and the law: What’s next? - Ben Seal (Knowable Magazine, 2024)

Problems of Qualification of Trafficking in Plants and Plant Parts Containing Psychoactive Substances and Mushrooms Containing Psilocybin and (or) Psilocin - Kulikov Aleksandr V.; Zheleznyak Ilya Yu. (Drug control, 2024)

UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study. - Song-Smith C; Jacobs E; Rucker J; Saint M; Cooke J; Schlosser M (BMJ open, 2024)

Pioneering Methods in Brain Optimization and Mental Health Treatment. - Kargbo RB (ACS medicinal chemistry letters, 2024)

Psilocybin poisoning from Psilocybe argentipes ingestion - Hiroshi Ito; Minori Fujita; Daiki Kobayashi (Visual Journal of Emergency Medicine, 2024)

Magic mushroom and zebrafish: A new recipe? - Robert Gerlai (Lab Animal, 2024)

New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. - Aaronson ST; Kozak Z (Med (New York, N.Y.), 2024)

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. - Rosenblat JD; Meshkat S; Doyle Z; Kaczmarek E; Brudner RM; Kratiuk K; Mansur RB; Schulz-Quach C; Sethi R; Abate A; Ali S; Bawks J; et al. (Med (New York, N.Y.), 2024)

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder - Brandon Weiss; Leor Roseman; Bruna Giribaldi; David Nutt; Robin Carhart-Harris; David Erritzøe (International Journal of Mental Health and Addiction, 2024)

Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent. - Ho C; Crawford JR (BMJ case reports, 2024)

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder. - Velit-Salazar MR; Shiroma PR; Cherian E (Brain sciences, 2024)

Psilocybin zur Behandlung depressiver Erkrankungen - Henning Hintzsche (BIOspektrum, 2024)

Post-traumatic stress symptoms, post-traumatic stress disorder, and post-traumatic growth among cancer survivors: a systematic scoping review of interventions. - Capaldi JM; Shabanian J; Finster LB; Asher A; Wertheimer JC; Zebrack BJ; Shirazipour CH (Health psychology review, 2024)

Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS) - Gomonit Munchelou M.; Skillman Britni; Swortwood Madeleine J. (Journal of Forensic Sciences, 2024)

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial. - Falchi-Carvalho M; Wießner I; Silva SRB; O Maia L; Barros H; Laborde S; Arichelle F; Tullman S; Silva-Costa N; Assunção A; Almeida R; Pantrigo ÉJ; et al. (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2024)

Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT receptor the unique player? - Sekssaoui M; Bockaert J; Marin P; Bécamel C (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2024)

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. - Rouaud A; Calder AE; Hasler G (Journal of psychopharmacology (Oxford, England), 2024)

Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometry - Wood Madeleine E; Brown Glenna J; Karschner Erin L; Seither Joshua Z; Brown Jordan T; Knittel Jessica L; Walterscheid Jeffrey P (Journal of Analytical Toxicology, 2024)

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. - Strickland JC; Garcia-Romeu A; Johnson MW (Psychedelic medicine (New Rochelle, N.Y.), 2024)

American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey. - Barnett BS; Arakelian M; Beebe D; Ontko J; Riegal C; Siu WO; Weleff J; Pope HG (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic. - Hibicke M; Billac G; Nichols CD (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. - Watford T; Masood N (Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology, 2024)

Psilocybin and the Development of Serotonin Toxicity. - Amarnani AD; Free MF; Baweja R (The primary care companion for CNS disorders, 2024)

Psychedelika-assistierte Psychotherapie - Aicher H. D.; Schmid Y.; Gasser P. (Die Psychotherapie, 2024)

The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey - Brouwer A; Brown JK; Erowid E; Erowid F; Thyssen S; Raison CL; Carhart-Harris RL. (Research Square, 2024)

Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction - Habelt B; Afanasenkau D; Schwarz C; Domanegg K; Kuchar M; Werner C; Minev IR; Spanagel R; Meinhardt MW; Bernhardt N. (Research Square, 2024)

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects. - Bhatt KV; Weissman CR (Npj mental health research, 2024)

Indigenous psilocybin mushroom practices: An annotated bibliography - Nicholas Spiers; Beatriz Caiuby Labate; Anna O. Ermakova; Patrick Farrell; Osiris Sinuhé González Romero; Ibrahim Gabriell; Nidia Olvera (Journal of Psychedelic Studies, 2024)

Development of a digital intervention for psychedelic preparation (DIPP). - McAlpine RG; Sacchet MD; Simonsson O; Khan M; Krajnovic K; Morometescu L; Kamboj SK (Scientific reports, 2024)

NIDA: Psilocybin mushroom seizures rose significantly - Alison Knopf (Alcoholism & Drug Abuse Weekly, 2024)

Effect of a single psilocybin treatment on Fos protein expression in male rat brain. - Funk D; Araujo J; Slassi M; Lanthier J; Atkinson J; Feng D; Lau W; Lê A; Higgins GA (Neuroscience, 2024)

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain. - Frautschi PC; Singh AP; Stowe NA; Yu JJ (AJNR. American journal of neuroradiology, 2024)

Psilocybin induces dose-dependent changes in functional network organization in rat cortex. - Silverstein BH; Kolbman N; Nelson A; Liu T; Guzzo P; Gilligan J; Lee U; Mashour GA; Vanini G; Pal D (bioRxiv: the preprint server for biology, 2024)

Tryptamine Derivatives of Norpsilocin Induce Psychedelic-Like Responses in Mice - Dirk Trauner; Kenny Calderon-Godinez (Synfacts, 2024)

The Effects of Psychedelics on Neuronal Physiology. - Hatzipantelis CJ; Olson DE (Annual review of physiology, 2024)

Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. - Hernandez-Leon A; Escamilla-Orozco RI; Tabal-Robles AR; Martínez-Vargas D; Romero-Bautista L; Escamilla-Soto G; González-Romero OS; Torres-Valencia M; González-Trujano ME (Journal of ethnopharmacology, 2024)

Repeat Dosing of Psilocybin in Headache Disorders - Yale University (ClinicalTrials.gov, 2024)

Effects of DMT on mental health outcomes in healthy volunteers. - Timmermann C; Zeifman RJ; Erritzoe D; Nutt DJ; Carhart-Harris RL (Scientific reports, 2024)

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. - Pagni BA; Petridis PD; Podrebarac SK; Grinband J; Claus ED; Bogenschutz MP (Scientific reports, 2024)

Psychedelics and sexual functioning: a mixed-methods study. - Barba T; Kettner H; Radu C; Peill JM; Roseman L; Nutt DJ; Erritzoe D; Carhart-Harris R; Giribaldi B (Scientific reports, 2024)

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. - Breeksema JJ; Niemeijer A; Krediet E; Karsten T; Kamphuis J; Vermetten E; van den Brink W; Schoevers R (Scientific reports, 2024)

A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use - Johns Hopkins University (ClinicalTrials.gov, 2024)

Psilocybin gegen Depressionen - Thomas Müller (CME, 2024)

Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD - Sara De Martin; Daniela Gabbia; Martina Colognesi; Andrea Rinaldi; Luciano Cascione; Ilaria Zanotto; Katia Sayaf; Stefano Comai; Andrea Mattarei; Marco Banzato; Gianfranco Pasut; Franco Folli; et al. (Digestive and Liver Disease, 2024)

Effect of psilocybin on pain - Alexandra Le Bras (Lab Animal, 2024)

Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. - Agin-Liebes G; Nielson EM; Zingman M; Kim K; Haas A; Owens LT; Rogers U; Bogenschutz M (Psychology of addictive behaviors: journal of the Society of Psychologists in Addictive Behaviors, 2024)

The development of psilocybin therapy for treatment-resistant depression: an update. - Borissova A; Rucker JJ (BJPsych bulletin, 2024)

The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. - Videira NB; Nair V; Paquet V; Calhoun D (Journal of applied toxicology: JAT, 2024)

The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. - Sicignano D; Hernandez AV; Schiff B; Elmahy N; White CM (Current medical research and opinion, 2024)

Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT receptor agonist TCB-2 in male DBA/2J mice. - Fletcher PJ; Li Z; Ji XD; Lê AD (Pharmacology, biochemistry, and behavior, 2024)

Do the therapeutic effects of psilocybin involve actions in the gut? - Reed F; Foldi CJ (Trends in pharmacological sciences, 2024)

Synthetic surprise as the foundation of the psychedelic experience. - De Filippo R; Schmitz D (Neuroscience and biobehavioral reviews, 2024)

Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry - Goff Roman; Smith Morgan; Islam Sabrina; Sisley Sue; Ferguson Jonathan; Kuzdzal Scott; Badal Sunil; Kumar Arun Babu; Sreenivasan Uma; Schug Kevin A. (Analytica Chimica Acta, 2024)

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey. - Plourde L; Chang SL; Farzin H; Gagnon P; Hébert J; Foxman R; Deschamps P; Provost F; Masse-Grenier M; Stephan JF; Cheung K; Joly Y; et al. (Palliative medicine, 2024)

Will Psilocybin-Assisted Therapy Reduce the Incidence of Medical Assistance in Dying? - Cho M; Rosenbaum D; Schneider E; Hales S (Journal of palliative medicine, 2024)

The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer. - Foster K; Morrison I; Tyler M; Delgoda R (Fungal biology, 2024)

A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder. - Norred MA; Zuschlag ZD; Hamner MB (Drugs, 2024)

Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach - Phil Wolfson; Gita Vaid (Frontiers in Psychiatry, 2024)

Psilocybin-assisted psychotherapy for cancer patients - Houman Farzin (International Journal of Whole Person Care, 2024)

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation. - Gojani EG; Wang B; Li DP; Kovalchuk O; Kovalchuk I (Genes, 2024)

The Effects of Psilocybin on Lipopolysaccharide-Induced Inflammation in THP-1 Human Macrophages - Esmaeel Ghasemi Gojani; Bo Wang; Dongping Li; Olga Kovalchuk; Igor Kovalchuk (Psychoactives, 2024)

Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice - Timur Zanikov; Marta Gerasymchuk; Gregory Ian Robinson; Esmaeel Ghasemi Gojani; Shima Asghari; Alyssa Groves; Mackenzie Cameron; Rocio Rodriguez-Juarez; Alexandra Snelling; Darryl Hudson; Anna Fiselier; Olga Kovalchuk; et al. (Biocatalysis and Agricultural Biotechnology, 2024)

Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2024)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD - Massachusetts General Hospital (ClinicalTrials.gov, 2024)

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists - Payal Ghosh; Debjeet Sur (Current Psychiatry Research and Reviews, 2024)

Psilocybin biphasically modulates cortical and behavioral activity in mice - Brockett AT; Francis NA. (bioRxiv, 2024)

Psychedelics for mental health: a biochemical perspective - Javier González-Maeso (The Biochemist, 2024)

Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action - Imperial College London (ClinicalTrials.gov, 2024)

Psychedelic-like Activity of Norpsilocin Analogues. - Sherwood AM; Burkhartzmeyer EK; Williamson SE; Baumann MH; Glatfelter GC (ACS chemical neuroscience, 2024)

Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review. - Lo DF; Zia H; Rajkumar P; Thakur A; O'Donnell H (The primary care companion for CNS disorders, 2024)

Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma - Kelsey Klute; Lou Lukas; Soonjo Hwang; Yeongjin Gwon; Mridula Krishnan; Jean L. Grem; Sunil R. Hingorani; Jody Koenig Kellas (Cancer Research, 2024)

How should psychotherapy proceed when adjoined with psychedelics? - Marc J. Weintraub; David J. Miklowitz (World Psychiatry, 2024)

MicroRNAs underlying the antidepressant effect of psilocybin - Establishing an nCounter pipeline for microRNA-quantification in the pig brain - Kaadt E; Søkilde R; Hansen H; Raval N; Lundgaard L; Just J; Knudsen G; Elfving B. (Research Square, 2024)

Psilocybin virker godt mot depresjon - Jørgen Østensjø (Tidsskrift for Den norske legeforening, 2024)

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study - Swanson L; Jungers S; Varghese R; Cullen KR; Evans MD; Nielson J; Schallmo M. (PsyArXiv, 2024)

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study - Link Swanson; Sophia Jungers; Ranji Varghese; Kathryn R. Cullen; Michael D Evans; Jessica L. Nielson; Michael-Paul Schallmo (PsyArXiv, 2024)

Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. - Duan W; Cao D; Wang S; Cheng J (Chemical reviews, 2024)

Rapid-acting antidepressant drugs modulate affective bias in rats. - Hinchcliffe JK; Stuart SA; Wood CM; Bartlett J; Kamenish K; Arban R; Thomas CW; Selimbeyoglu A; Hurley S; Hengerer B; Gilmour G; Robinson ESJ (Science translational medicine, 2024)

In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin - Jones Nathan T.; Wagner Laura; Hahn Molly C. Pellitteri; Scarlett Cameron O.; Wenthur Cody J. (Frontiers in Psychiatry, 2024)

Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq - Huang Z; Wei X; Wang Y; Tian J; Dong J; Liang B; Lu L; Zhang W. (bioRxiv, 2024)

Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin - L. Richter; Jozef Al-Gousous; Gabriel Lima Barros de Araújo; Neal M. Davies; Raimar Löbenberg (Journal of Drug Delivery Science and Technology, 2024)

Usikker effekt av psilocybin ved anoreksi - Haakon B. Benestad (Tidsskrift for Den norske legeforening, 2024)

Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder - Johns Hopkins University (ClinicalTrials.gov, 2024)

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review - Shore R; Dobson K; Thomson N; Barnim N; Bergman H; Rideout K; McKeown S; Olmstead MC; Goldie C; Dumont E. (bioRxiv, 2024)

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial - Vanderijst L; Hever F; Buot A; Dauré C; Benoit J; Hanak C; Veeser J; Morgiève M; Campanella S; Kornreich C; Mallet L; Leys C; et al. (Research Square, 2024)

Psilocybin as a treatment for psychiatric disorders: a review of the literature - Verneri Pellinen (Työväentutkimus Vuosikirja, 2024)

Differential effects of psychedelics and classical antidepressants on TrkB dimerization and neurotrophic signalling - Paula Pastor Muñoz (Työväentutkimus Vuosikirja, 2024)

Perceptions of Psychedelics: University Students' Attitudes and Motives for Psilocybin Use - Shayla Frinton (UVic's Research and Learning Repository, 2024)

Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary - Michael D. Alpert; Kelley C. O’Donnell; Casey A. Paleos; Evan Sola; Christopher S. Stauffer; Anne Catherine Wagner; Christopher R. Nicholas; Michael C. Mithoefer (American Journal of Psychiatry, 2024)

Psilocybin’s Role in Major Depressive Disorder: A Scoping Review - Barajas; Carlos (Digital Commons - George Fox University (George Fox University), 2024)

RAPIDLY TRADING DOWN DEPRESSION'S3 PILLARS TO 5HT3-RECEPTORS THROUGH ECT OR PSILOCYBIN? - R.S. Treviranus; Gottfried (University of Zagreb University Computing Centre (SRCE), 2024)

Referee report. For: A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. [version 2; peer review: 1 approved with reservations, 1 not approved] - Sebastiaan Werten (Faculty of 1000 Research Ltd, 2024)

Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 2 approved with reservations] - Manoj K. Doss (Faculty of 1000 Research Ltd, 2024)

Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved, 3 approved with reservations] - Rayyan Zafar (Faculty of 1000 Research Ltd, 2024)

Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved with reservations] - Manesh Girn (Faculty of 1000 Research Ltd, 2024)

Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 3 approved with reservations] - Lorenzo Pasquini (Faculty of 1000 Research Ltd, 2024)

Panini and Psilocybin - Bridget Verhaaren (Dialogue A Journal of Mormon Thought, 2024)

Changes in positive and negative affect in participants with treatment-resistant depression following COMP360 psilocybin treatment - Matthew B. Young; J. Chai-Rees; Anna Nowakowska; Jeng-Yu Tsai; Guy M. Goodwin (Neuroscience Applied, 2024)

Psilocybin vs Escitalopram for depression: 6-month follow-up - Thomas Barba; David Erritzøe; Kyle T. Greenway; Rinki Murphy; John Martell; Christopher Timmermann; Ashleigh Murphy-Beiner; Bruna Giribaldi; Michelle Baker Jones; Brandon Weiss; Robin Carhart-Harris (Neuroscience Applied, 2024)

Effects of psilocybin and sleep quality on brain water diffusivity and microstructure in healthy individuals and chronic cluster headache patients - Kristoffer Brendstrup-Brix; Patrick M. Fisher; Dea Siggaard Stenbæk; Anja Sofie Petersen; Stéphane Armand; Drummond E-Wen McCulloch; Maja Rou Marstrand-Joergensen; Sara Marie Ulv Larsen; Annette Johansen; Rigmor Jensen; Gitte M. Knudsen; M. Madsen (Neuroscience Applied, 2024)

Neural effects of psilocybin-treatment in patients with treatment-resistant depression - C. Schmitz; Hana Adolphi; Michael Frank; E. Seeger; Maciej Musiał; Moritz Spangemacher; Michael Koslowski; Lea J. Mertens; Florian Schlagenhauf; Gerhard Gründer (Neuroscience Applied, 2024)

Insights into the serotonergic mechanisms of psilocybin-induced improvements in anorexia-like behaviour in female rats - Kyna-Anne Conn; Laura K Milton; Kaixin Huang; Hermany Munguba; Jaana Ruuska; Mónica Lemus; Erin Greaves; Jihane Homman-Ludiye; Brian J. Oldfield; Claire J. Foldi (Neuroscience Applied, 2024)

Associations between behavioral and neuronal changes in self-referential processing following a single, moderate dose of psilocybin in depressed patients - L. Belinger; Flora Moujaes; Robin von Rotz; Nathalie M. Rieser; Marcus Herdener; Franz X. Vollenweider; Katrin H. Preller (Neuroscience Applied, 2024)

Evaluation of the long-term cognitive effects of psilocybin in a chronic stress mouse model - Nerea Martínez-Álvarez; Ines Erkizia-Santamaría; Elena Hernández-Hernández; Amaia M. Erdozain; J. Javier Meana; J.E. Ortega (Neuroscience Applied, 2024)

The Therapeutic Potential of Psilocybin for Depression - Watford Tessa (Scientia, 2024)

Cannabis and Psilocybin: Insurance Reimbursement, Legalization, and Rescheduling - Elena Markos (Health Law Outlook, 2024)

Psychedelics: The New Kid on the Block - Prosenjit Ghosh; Avinash Desousa (Annals of Indian Psychiatry, 2024)

Exploring the molecular basis of treatment-resistant depression: Discoveries from a rat model and psilocybin therapy - Agata Korlatowicz; Katarzyna Latocha; Paulina Pabian; Ryszard Bugno; Adam S. Hogendorf; Tamás Kovács; Andrzej J. Bojarski; Zoltán V. Varga; Agata Faron-Górecka (Neuroscience Applied, 2024)

Introduction to the Special Section on Psychedelics Research and Treatment - Dominic Sisti (Perspectives in biology and medicine, 2024)

Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders - Correa RMS (Annals of Bioethics & Clinical Applications, 2024)

Investigational COMP360 psilocybin treatment for treatment-resistant depression: assessing altered states of consciousness - N. Hewitt; J. Chai-Rees; Megan Croal; S. Mistry; Jeng-Yu Tsai; Matthew B. Young; Guy M. Goodwin (Neuroscience Applied, 2024)

Psilocybin for the treatment of posttraumatic stress disorder: A magic to treat a harmony of illusions? - Rakesh Khanna (Journal of Indira Gandhi Institute Of Medical Sciences, 2024)

Brazilian Psychedelic Science and the Frontiers of Psychiatry - Dráulio Barros de Araújo; Tiago Arruda Sanchez; Sidarta Ribeiro (Jornal Brasileiro de Psiquiatria, 2024)

Pharmacological characterization of psilocin affinity towards different 5-HT receptors and receptor regulation after psilocybin administration in pigs - Kolesnik E.; Navarro M. López; Raval N.R.; Ozenne B.; Hansen H.D. (Neuroscience Applied, 2024)

Educational Materials and Image Induction Increase Treatment Credibility. - Low F; Earleywine M (Journal of psychoactive drugs, 2024)

Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. - Gukasyan N; Narayan SK (Journal of psychoactive drugs, 2024)

Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. - Koning E; Brietzke E (Trends in psychiatry and psychotherapy, 2024)

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. - Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D (Psychological medicine, 2024)

Must Psilocybin Always "Assist Psychotherapy"? - Goodwin GM; Malievskaia E; Fonzo GA; Nemeroff CB (The American journal of psychiatry, 2024)

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM. - Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D (Psychological medicine, 2024)

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study. - Cavarra M; Mason NL; Kuypers KPC; Bonnelle V; Smith WJ; Feilding A; Kryskow P; Ramaekers JG (European journal of pain (London, England), 2024)

Potential Benefits of Psilocybin for Lupus Pain: A Case Report. - Gonzales SAB; Alexopoulos C; Arkfeld DG (Current rheumatology reviews, 2024)

The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. - Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME (Journal of psychopharmacology (Oxford, England), 2024)

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. - Jacobs E; Murphy-Beiner A; Rouiller I; Nutt D; Spriggs MJ (Neuroethics, 2024)

Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. - Heresco-Levy U; Lerer B (Molecular psychiatry, 2024)

The psychedelic effects of cannabis: A review of the literature. - Wolinsky D; Barrett FS; Vandrey R (Journal of psychopharmacology (Oxford, England), 2024)

Psilocybin and Other Classic Psychedelics in Depression. - Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D (Current topics in behavioral neurosciences, 2024)

Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. - Hovmand OR; Poulsen ED; Arnfred S (Journal of psychopharmacology (Oxford, England), 2024)

Drug-drug interactions involving classic psychedelics: A systematic review. - Halman A; Kong G; Sarris J; Perkins D (Journal of psychopharmacology (Oxford, England), 2024)

Psychedelia: The interplay of music and psychedelics. - Jerotic K; Vuust P; Kringelbach ML (Annals of the New York Academy of Sciences, 2024)

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. - Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A (Pharmacological research, 2024)

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. - Borkel LF; Rojas-Hernández J; Henríquez-Hernández LA; Santana Del Pino Á; Quintana-Hernández DJ (Expert review of clinical pharmacology, 2024)

Is there credible evidence to assert psilocybin-assisted therapy for depression? - Nogueira GN; Vasconcelos MMA; Souza FGM; Bisol LW (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2024)

Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom. - Simonsson O; Hendricks PS; Stenfors CU; Goldberg SB; Honk L; Osika W (Journal of psychopharmacology (Oxford, England), 2024)

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy. - O'Donnell KC; Anderson BT; Barrett FS; Bogenschutz MP; Grob CS; Hendricks PS; Kelmendi B; Nayak SM; Nicholas CR; Paleos CA; Stauffer CS; Gukasyan N (The American journal of psychiatry, 2024)

Is Poorly Assisted Psilocybin Treatment an Increasing Risk? - Schenberg EE; King F; da Fonseca JE; Roseman L (The American journal of psychiatry, 2024)

Psilocybin Without Psychotherapy: A Cart Without a Horse? - Earleywine M; De Leo J; Bhayana D; Rajanna B; Scott K (The American journal of psychiatry, 2024)

Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary. - Goodwin GM; Malievskaia E; Fonzo GA; Nemeroff CB (The American journal of psychiatry, 2024)

The safety of supported psilocybin use in Oregon. - Smith WR; Sisti DA; Appelbaum PS (Nature medicine, 2024)

CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. - Madsen MK; Petersen AS; Stenbaek DS; Sørensen IM; Schiønning H; Fjeld T; Nykjaer CH; Larsen SMU; Grzywacz M; Mathiesen T; Klausen IL; Overgaard-Hansen O; et al. (Headache, 2024)

Older adults in psychedelic-assisted therapy trials: A systematic review. - Bouchet L; Sager Z; Yrondi A; Nigam KB; Anderson BT; Ross S; Petridis PD; Beaussant Y (Journal of psychopharmacology (Oxford, England), 2024)

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. - Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; et al. (Current neuropharmacology, 2024)

Valuing the Acute Subjective Experience. - Cheung K; Earp BD; Yaden DB (Perspectives in biology and medicine, 2024)

[Up-to-Date on clinical and preclinical studies of psilocybin therapy]. - Ibi D (Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2024)

Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD). - Olivier B; Olivier JDA (Advances in experimental medicine and biology, 2024)

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction. - Vamvakopoulou IA; Nutt DJ (European addiction research, 2024)

Ayahuasca for the treatment of alcohol use disorder. - Marinho EAV; Serra YA; Oliveira-Lima AJ; Marcourakis T; Berro LF (International review of neurobiology, 2024)

Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders. - Martire G; Sipple D; Baron D; Gold MS; Lewandowski KU; Dennen CA; Sharafshah A; Elman I; Thanos PK; Modestino EJ; Badgaiyan RD; Pinhasov A; et al. (Journal of addiction psychiatry, 2024)

Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals. - Armand S; Larsen K; Madsen MK; Ozenne B; Preller KH; Knudsen GM; Stenbæk DS; Fisher PM (Neuroscience applied, 2024)

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. - McCulloch DE; Lopez JP; Dalla C; Castrén E; Erritzoe D; Frokjaer VG; Lundberg J; Preller KH; Fisher PM; Knudsen GM (Neuroscience applied, 2024)

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects. - E-Wen McCulloch D; Liechti ME; Kuypers KP; Nutt D; Lundberg J; Stenbæk DS; Goodwin GM; Gründer G; Butlen-Ducuing F; Haberkamp M; Thirstrup S; Knudsen GM (Neuroscience applied, 2024)

Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions. - Modlin NL; Creed M; Sarang M; Maggio C; Rucker JJ; Williamson V (Neuropsychiatric disease and treatment, 2024)

Effects of hallucinogenic drugs on the human heart. - Neumann J; Dhein S; Kirchhefer U; Hofmann B; Gergs U (Frontiers in pharmacology, 2024)

Keeping the promise: a critique of the current state of microdosing research. - Petranker R; Anderson T; Fewster EC; Aberman Y; Hazan M; Gaffrey M; Seli P (Frontiers in psychiatry, 2024)

Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. - Fang S; Yang X; Zhang W (Frontiers in psychiatry, 2024)

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. - Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Jankovsky A; Kichuk SA; et al. (Frontiers in psychiatry, 2024)

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey. - Glynos NG; Aday JS; Kruger D; Boehnke KF; Lake S; Lucas P (Frontiers in psychiatry, 2024)

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS (American journal of therapeutics, 2024)

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin. - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS (American journal of therapeutics, 2024)

Where do the symptoms come from in depression? Topography and dynamics matter. - Çatal Y; Northoff G (Brain communications, 2024)

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. - Robinson CL; Fonseca ACG; Diejomaoh EM; D'Souza RS; Schatman ME; Orhurhu V; Emerick T (Journal of pain research, 2024)

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. - Levin AW; Lancelotta R; Sepeda ND; Gukasyan N; Nayak S; Wagener TL; Barrett FS; Griffiths RR; Davis AK (PloS one, 2024)

Safety pharmacology of acute psilocybin administration in healthy participants. - Straumann I; Holze F; Becker AM; Ley L; Halter N; Liechti ME (Neuroscience applied, 2024)

Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics. - Thomas KL; Jesse R; Mehtani NJ; Mitchell JM; Anderson BT (Journal of psychoactive drugs, 2024)

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists. - Sandbrink JD; Johnson K; Gill M; Yaden DB; Savulescu J; Hannikainen IR; Earp BD (AJOB neuroscience, 2024)

The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov. - Norring SA; Spigarelli MG (Drug design, development and therapy, 2024)

Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators. - Lerer E; Botvinnik A; Shahar O; Grad M; Blakolmer K; Shomron N; Lotan A; Lerer B; Lifschytz T (Frontiers in pharmacology, 2024)

Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress. - Wang JR; Mendez Araque SJ; Micciche G; McMillan A; Coughlin E; Mattiola R; English D; Kaliebe K (Frontiers in psychiatry, 2024)

Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. - Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; et al. (Frontiers in psychiatry, 2024)

Attitudes of European psychiatrists on psychedelics: a qualitative study. - Žuljević MF; Breški N; Kaliterna M; Hren D (Frontiers in psychiatry, 2024)

Effect of oral tryptamines on the gut microbiome of rats-a preliminary study. - Xu M; Kiss AJ; Jones JA; McMurray MS; Shi H (PeerJ, 2024)

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity. - Wang CK; Kim G; Aleksandrova LR; Panenka WJ; Barr AM (Frontiers in pharmacology, 2024)

Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action". - Bornemann J; Close JB; Ahmad K; Barba T; Godfrey K; Macdonald L; Erritzoe D; Nutt D; Carhart-Harris R (Frontiers in psychiatry, 2024)

Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. - Szafoni S; Gręblowski P; Grabowska K; Więckiewicz G (Frontiers in psychiatry, 2024)

Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension. - Jones GM; Ricard JA; Nock MK (Frontiers in psychiatry, 2024)

Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data. - Bienemann B; Barbosa AR; Cruz LVMD; Multedo M; Mograbi D (Journal of psychoactive drugs, 2024)

Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review. - Lee HJ; Tsang VW; Chai BS; Lin MC; Howard A; Uy C; Elefante JO (Journal of psychoactive drugs, 2024)

Psilocybin for the treatment of Alzheimer's disease. - Zheng S; Ma R; Yang Y; Li G (Frontiers in neuroscience, 2024)

Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. - Do A; Michaud V; Stephan JF; Moreau M; Benoît É; Bérubé FA; Bibaud-De Serres A; Taillefer A; Vincent P (Frontiers in psychiatry, 2024)

Revisiting psychiatry's relationship with spirituality. - DeBonis K (Frontiers in psychiatry, 2024)

Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants. - Bhagavan C; Kanaan R; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Oliver G; Mayne D; McKernon D; et al. (Psychiatric research and clinical practice, 2024)

[The nursing role in psychedelic-assisted psychotherapy]. - Amberger C; Szczesniak L (Revue de l'infirmiere, 2024)

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. - VanderZwaag B; Garcia-Romeu A; Garcia-Barrera MA (Therapeutic advances in psychopharmacology, 2024)

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis. - Chen MH; Cheng SL; Kao YC; Tseng PT; Hsu CW; Yu CL; Yang FC; Thompson T; Hsu TW; Liang CS (Frontiers in psychiatry, 2024)

Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects. - Martial C; Carhart-Harris R; Timmermann C (Neuroscience of consciousness, 2024)

Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. - Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR (Journal of psychoactive drugs, 2024)

On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked. - Korman BA (Journal of psychoactive drugs, 2024)

Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City. - Palamar JJ; Rutherford C; Le A; Keyes KM (Journal of psychoactive drugs, 2024)

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders. - Wong S; Yu AY; Fabiano N; Finkelstein O; Pasricha A; Jones BDM; Rosenblat JD; Blumberger DM; Mulsant BH; Husain MI (Journal of psychoactive drugs, 2024)

CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality. - Gobbi G (Journal of psychiatry & neuroscience: JPN, 2024)

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. - Li LJ; Mo Y; Shi ZM; Huang XB; Ning YP; Wu HW; Yang XH; Zheng W (Frontiers in psychiatry, 2024)

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia. - Mamat R; Rashid RA; Shin SM; Ibrahim B; Wahab S; Ahmad A (Journal of addictive diseases, 2024)

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada. - Kim K; Yusuf A; Sud A; Persaud N; Kirubarajan A; Moller M; Lloyd T; O'Neill B (PloS one, 2024)

A narrative exploration of psilocybin's potential in mental health. - Min H; Park SY; Park J; Na S; Lee HS; Kim T; Ham J; Park YT (Frontiers in psychiatry, 2024)